155 related articles for article (PubMed ID: 6404918)
1. Bone density in amenorrheic women with and without hyperprolactinemia.
Schlechte JA; Sherman B; Martin R
J Clin Endocrinol Metab; 1983 Jun; 56(6):1120-3. PubMed ID: 6404918
[TBL] [Abstract][Full Text] [Related]
2. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea.
Schlechte J; el-Khoury G; Kathol M; Walkner L
J Clin Endocrinol Metab; 1987 May; 64(5):1021-6. PubMed ID: 3558723
[TBL] [Abstract][Full Text] [Related]
3. Effects of prolactin and estrogen deficiency in amenorrheic bone loss.
Klibanski A; Biller BM; Rosenthal DI; Schoenfeld DA; Saxe V
J Clin Endocrinol Metab; 1988 Jul; 67(1):124-30. PubMed ID: 3379129
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral content and levels of gonadotropins and estrogens in amenorrheic running women.
Fisher EC; Nelson ME; Frontera WR; Turksoy RN; Evans WJ
J Clin Endocrinol Metab; 1986 Jun; 62(6):1232-6. PubMed ID: 3700585
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral content of amenorrheic and eumenorrheic athletes.
Drinkwater BL; Nilson K; Chesnut CH; Bremner WJ; Shainholtz S; Southworth MB
N Engl J Med; 1984 Aug; 311(5):277-81. PubMed ID: 6738640
[TBL] [Abstract][Full Text] [Related]
6. Catecholamines and pituitary function. I. Effects of catecholamine synthesis inhibition and subsequent catecholamine infusion on gonadotropin and prolactin serum levels in normal cycling women and in women with hyperprolactinemic amenorrhea.
Nicoletti I; Filipponi P; Sfrappini M; Fedeli L; Petrelli S; Gregorini G; Santeusanio F; Brunetti P
Horm Res; 1984; 19(3):158-70. PubMed ID: 6425187
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin and prolactin pulsations in hyperprolactinemic women before and during bromocriptine therapy.
Klibanski A; Beitins IZ; Merriam GR; McArthur JW; Zervas NT; Ridgway EC
J Clin Endocrinol Metab; 1984 Jun; 58(6):1141-7. PubMed ID: 6427260
[TBL] [Abstract][Full Text] [Related]
8. Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors.
Schlechte JA; Sherman BM; Chapler FK; VanGilder J
J Clin Endocrinol Metab; 1986 Jun; 62(6):1296-301. PubMed ID: 3084539
[TBL] [Abstract][Full Text] [Related]
9. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea.
Nicoletti I; Ambrosi F; Giammartino C; Fedeli L; Mannarelli C; Filipponi P
Horm Metab Res; 1986 Jul; 18(7):479-84. PubMed ID: 3091473
[TBL] [Abstract][Full Text] [Related]
10. Catecholamines and pituitary function. 2. Prolactin response to different dopamine doses in normal cycling women and patients with prolactin-secreting pituitary tumors, both before and after endogenous catecholamine synthesis inhibition.
Nicoletti I; Filipponi P; Fedeli L; Gregorini G; Ambrosi F; Sfrappini M; Santeusanio F; Brunetti P
Horm Metab Res; 1984 Dec; 16(12):658-62. PubMed ID: 6441763
[TBL] [Abstract][Full Text] [Related]
11. Vertebral body bone mineral content in hyperprolactinemic women.
Koppelman MC; Kurtz DW; Morrish KA; Bou E; Susser JK; Shapiro JR; Loriaux DL
J Clin Endocrinol Metab; 1984 Dec; 59(6):1050-3. PubMed ID: 6490793
[TBL] [Abstract][Full Text] [Related]
12. Sex hormones in amenorrheic women with alcoholic liver disease.
Välimäki M; Pelkonen R; Salaspuro M; Härkönen M; Hirvonen E; Ylikahri R
J Clin Endocrinol Metab; 1984 Jul; 59(1):133-8. PubMed ID: 6427268
[TBL] [Abstract][Full Text] [Related]
13. Increase in bone mass after treatment of hyperprolactinemic amenorrhea.
Klibanski A; Greenspan SL
N Engl J Med; 1986 Aug; 315(9):542-6. PubMed ID: 3736637
[TBL] [Abstract][Full Text] [Related]
14. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia.
Schlechte J; Walkner L; Kathol M
J Clin Endocrinol Metab; 1992 Sep; 75(3):698-703. PubMed ID: 1517357
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia.
Kishimoto T; Watanabe K; Shimada N; Makita K; Yagi G; Kashima H
J Clin Psychiatry; 2008 Mar; 69(3):385-91. PubMed ID: 18278991
[TBL] [Abstract][Full Text] [Related]
16. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women.
Weisinger JR; Gonzalez L; Alvarez H; Hernandez E; Carlini RG; Capriles F; Cerviño M; Martinis R; Paz-Martínez V; Bellorín-Font E
Kidney Int; 2000 Jul; 58(1):331-5. PubMed ID: 10886579
[TBL] [Abstract][Full Text] [Related]
17. Significance of hyperprolactinemia in 70 women with amenorrhea.
Potashnik G; Bar-Ziv J; Glick S; Shoham A; Ben-Aderet N
Isr J Med Sci; 1978 Jul; 14(7):753-61. PubMed ID: 681167
[TBL] [Abstract][Full Text] [Related]
18. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine.
Sauder SE; Frager M; Case GD; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1984 Nov; 59(5):941-8. PubMed ID: 6434588
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin responses to gonadotropin-releasing hormone and prolactin responses to thyrotropin-releasing hormone and metoclopramide in women with amenorrhea and insulin-treated diabetes mellitus.
Djursing H; Hagen C; Nyholm HC; Carstensen L; Andersen AN
J Clin Endocrinol Metab; 1983 May; 56(5):1016-21. PubMed ID: 6403566
[TBL] [Abstract][Full Text] [Related]
20. Naloxone increases the frequency of pulsatile luteinizing hormone secretion in women with hyperprolactinemia.
Cook CB; Nippoldt TB; Kletter GB; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Nov; 73(5):1099-105. PubMed ID: 1939525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
